CRISPR THERAPEUTICS H-1B Visa Sponsorship & Salary Data

The median H-1B salary at CRISPR THERAPEUTICS is $112,000, based on 105 certified filings from FY 2020 to FY 2026. This is 7% lower than the national H-1B median salary of $120,000. Compensation at CRISPR THERAPEUTICS reflects their market positioning, with entry-level roles starting around $94,774 and senior positions reaching $155,068 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at CRISPR THERAPEUTICS range from $85,038 at the 10th percentile to $155,068 at the 90th percentile, showing a $70,030 spread across experience levels and roles. The 25th percentile is $94,774 and the 75th percentile is $133,315.

Yes, CRISPR THERAPEUTICS actively sponsors H-1B visas in FY 2026. In the most recent fiscal year (FY 2026), CRISPR THERAPEUTICS filed 4 H-1B labor condition applications with 4 certified and 0 denied, at a median salary of $123,838. Across FY 2020–2026, they have filed 111 total H-1B applications with 105 certified and a 1.8% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. CRISPR THERAPEUTICS sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2026), CRISPR THERAPEUTICS filed 4 H-1B applications, with 4 certified and 0 denied. Over 7 years of data, CRISPR THERAPEUTICS has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

CRISPR THERAPEUTICS's LCA (Labor Condition Application) denial rate is 1.8%, with 2 out of 111 applications denied across all years. This translates to a 98.2% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating CRISPR THERAPEUTICS as a potential H-1B sponsor.

This is a good approval rate, comparable to industry averages. CRISPR THERAPEUTICS demonstrates reliable H-1B sponsorship practices.

CRISPR THERAPEUTICS sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 105 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles CRISPR THERAPEUTICS most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at CRISPR THERAPEUTICS:

The most frequently sponsored role is Research Associate II with 22 filings at a median salary of $86,000. This is followed by Senior Research Associate (20 filings) and Principal Research Associate.

CRISPR THERAPEUTICS's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where CRISPR THERAPEUTICS sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top CRISPR THERAPEUTICS H-1B locations:

The largest H-1B hub for CRISPR THERAPEUTICS is Boston, MA with 55 filings at a median salary of $113,000. The highest-paying location is Shrewsbury, MA at $200,000 median. Salaries range from $107,000 to $200,000 across office locations.

CRISPR THERAPEUTICS's median H-1B salary has increased by +13% from FY 2020 ($110,000) to FY 2026 ($123,838). Tracking salary trends over time reveals how CRISPR THERAPEUTICS adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at CRISPR THERAPEUTICS.

Year-by-year breakdown:

• FY 2022: $105,000 (20 certified)
• FY 2023: $115,000 (18 certified)
• FY 2024: $105,315 (21 certified)
• FY 2025: $127,077 (12 certified)
• FY 2026: $123,838 (4 certified)

CRISPR THERAPEUTICS has maintained steady salary growth for H-1B positions over this period.

CRISPR THERAPEUTICS primarily files H-1B applications at Wage Level II, accounting for 50% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making CRISPR THERAPEUTICS's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

With 90% of positions at Level II or higher, CRISPR THERAPEUTICS typically offers competitive wages above entry-level. Higher wage levels receive priority in the H-1B lottery.

CRISPR THERAPEUTICS's median H-1B salary of $112,000 is 7% lower than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating CRISPR THERAPEUTICS's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare CRISPR THERAPEUTICS's offerings with similar companies in your field for a more accurate assessment.

CRISPR THERAPEUTICS's H-1B salaries are competitive with industry averages. The 105 total filings indicate active H-1B sponsorship.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. CRISPR THERAPEUTICS files 10% of positions at Level I, which may face more lottery competition under wage-level prioritization rules.

With 105 certified filings, CRISPR THERAPEUTICS invests significantly in H-1B sponsorship. The company's 1.8% denial rate suggests solid H-1B processing practices.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.